The pharmaceutical company’s CFO on an unconventional path to the C-suite, what it means when investors trust you can generate enough cash and why corporate purpose is part of the fabric of Roche
When you’re the CFO of a 261.6bn Swiss franc ($333.5 bn) market cap pharmaceutical giant like Roche, you don’t necessarily have to be ‘the roadshow guy’.
Instead, Dr Alan Hippe tells IR Impact that what he loves about the IR work he does are conferences – which are ‘super efficient’ – and investor one-on-ones, which allow you to make a real difference in investor opinion.
In our latest installment of The CFO series, Hippe talks about what he looks for from his head of IR – having worked with the likes of Dr Karl Mahler and Dr Bruno Eschli, who has led the firm’s IR efforts for more than four years – as well as his own role in the function and why his work at Roche has made his mom proud.
Enjoy access to this and more – for free!
Log in or create your free My IR – Essentials account to:
- Get access to 3 free IR deep dives
- More than 100 pieces of insight, plus our exclusive CFO interviews
- Save favorites and get personalized content on your dashboard
- Enjoy 10% off all IR forums
